Physician profile
Nicholas M Lytle
NPI 1588050652
$11,413.28
in general payments reported to CMS, 2019-2025
31 companies · $6,312 in 2025
The $6,312 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $310 · 2022: $319 · 2023: $2,421 · 2024: $1,858 · 2025: $6,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,224 · Consulting Fee: $3,400 · Travel and Lodging: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,224.26 |
| Consulting Fee | $3,400.00 |
| Travel and Lodging | $966.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,215.78 | 2022-2025 | |
| Amgen INC. | $952.68 | 2022-2025 | Tavneos, Krystexxa, Enbrel |
| Janssen Biotech, INC. | $875.37 | 2019-2025 | Tremfya |
| Octapharma USA, INC. | $574.11 | 2023-2024 | Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $460.97 | 2022-2025 | |
| Glaxosmithkline, LLC. | $400.04 | 2020-2025 | Benlysta |
| Lilly USA, LLC | $344.03 | 2022-2025 | Taltz, Olumiant |
| Ucb, INC. | $311.42 | 2023-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $229.10 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $220.69 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $185.97 | 2022-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $185.83 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $176.97 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.85 | 2022-2024 | Ofev, Cyltezo |
| Sobi, INC | $140.43 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $138.35 | 2023-2025 | Idacio |
| Pfizer INC. | $124.50 | 2022-2025 | |
| Organon LLC | $123.97 | 2023-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $98.76 | 2024-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $97.89 | 2023-2024 | |
| Genentech USA, INC. | $95.31 | 2023-2024 | Actemra, Rituxan |
| Sandoz INC. | $81.66 | 2023-2025 | Hyrimoz |
| Radius Health, INC. | $57.38 | 2025 | |
| Almatica Pharma LLC | $30.78 | 2024-2025 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $27.90 | 2023 | Cuvitru |
| Mallinckrodt Hospital Products INC. | $25.92 | 2025 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $22.86 | 2024 | Arcalyst |
| Mylan Institutional INC. | $22.67 | 2023 | Hulio |
| Scilex Pharmaceuticals INC. | $18.92 | 2024 | |
| Celgene Corporation | $18.28 | 2024 | Orencia |
| Azurity Pharmaceuticals, INC. | $13.89 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lytle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.